The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Johan F. Vansteenkiste

Respiratory Oncology Unit (Pulmonology)

University Hospital Gasthuisberg

Herestraat 49

3000, Leuven

Belgium

[email]@uz.kuleuven.ac.be

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Herestraat 49, 3000, Leuven, Belgium. 1997 - 2008
  • Department of Pulmonology, Respiratory Oncology Unit and PET Center (Nuclear Medicine), Leuven Lung Cancer Group, Leuven, Belgium. 2006

References

  1. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Vansteenkiste, J., Van Cutsem, E., Dumez, H., Chen, C., Ricker, J.L., Randolph, S.S., Schöffski, P. Invest. New. Drugs (2008) [Pubmed]
  2. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. Vansteenkiste, J., Lara, P.N., Le Chevalier, T., Breton, J.L., Bonomi, P., Sandler, A.B., Socinski, M.A., Delbaldo, C., McHenry, B., Lebwohl, D., Peck, R., Edelman, M.J., Edelman, M. J. Clin. Oncol. (2007) [Pubmed]
  3. Staging of lung cancer. Wynants, J., Stroobants, S., Dooms, C., Vansteenkiste, J. Radiol. Clin. North Am. (2007) [Pubmed]
  4. Improving patient management in metastatic non-small cell lung cancer. Vansteenkiste, J. Lung. Cancer (2007) [Pubmed]
  5. Positron emission tomography in nonsmall cell lung cancer. Vansteenkiste, J., Dooms, C. Curr. Opin. Oncol (2007) [Pubmed]
  6. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals. Vansteenkiste, J., Wauters, I. Expert. Rev. Anticancer. Ther (2007) [Pubmed]
  7. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management. Vansteenkiste, J.F. Cancer Treat. Rev. (2006) [Pubmed]
  8. Second-line therapeutic options in non-small-cell lung cancer. Vansteenkiste, J. Lung. Cancer (2006) [Pubmed]
  9. PET scan in lung cancer: current recommendations and innovation. Vansteenkiste, J.F., Stroobants, S.S. J. Thorac. Oncol (2006) [Pubmed]
  10. The future of adjuvant chemotherapy for resected non-small cell lung cancer. Vansteenkiste, J.F., Schildermans, R.H. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  11. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Vansteenkiste, J., Wauters, I. Expert. Opin. Pharmacother (2005) [Pubmed]
  12. Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Vansteenkiste, J., Tomita, D., Rossi, G., Pirker, R. Support. Care. Cancer (2004) [Pubmed]
  13. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Vansteenkiste, J. Expert. Rev. Anticancer. Ther (2004) [Pubmed]
  14. Positron emission tomography in the management of non-small cell lung cancer. Vansteenkiste, J.F., Stroobants, S.G. Hematol. Oncol. Clin. North Am. (2004) [Pubmed]
  15. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Vansteenkiste, J., Fischer, B.M., Dooms, C., Mortensen, J. Lancet Oncol. (2004) [Pubmed]
  16. Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Vansteenkiste, J., Vandebroek, J., Nackaerts, K., Dooms, C., Galdermans, D., Bosquée, L., Delobbe, A., Deschepper, K., Van Kerckhoven, W., Vandeurzen, K., Deman, R., D'Odemont, J.P., Siemons, L., Van den Brande, P., Dams, N. Lung. Cancer (2003) [Pubmed]
  17. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia. Vansteenkiste, J., Rossi, G., Foote, M. Expert. Opin. Biol. Ther (2003) [Pubmed]
  18. PET scan in the staging of non-small cell lung cancer. Vansteenkiste, J.F. Lung. Cancer (2003) [Pubmed]
  19. Pharmacotherapy of chemotherapy-induced anaemia. Vansteenkiste, J., Van-Steenkiste, J. Expert. Opin. Pharmacother (2003) [Pubmed]
  20. Imaging in lung cancer: positron emission tomography scan. Vansteenkiste, J.F. Eur. Respir. J. Suppl (2002) [Pubmed]
  21. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., Siena, S., Gateley, J., Tomita, D., Colowick, A.B., Musil, J. J. Natl. Cancer Inst. (2002) [Pubmed]
  22. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Vansteenkiste, J., Poulsen, E., Rossi, G., Glaspy, J. Oncology (Williston Park, N.Y.) (2002) [Pubmed]
  23. Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Vansteenkiste, J.F., Bomans, P., Verbeken, E.K., Nackaerts, K.L., Demedts, M.G. Lung. Cancer (2001) [Pubmed]
  24. Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study. Vansteenkiste, J., Gatzemeier, U., Manegold, C., Hanauske, A., Weynants, P., Bosquée, L., Blatter, J., Mansouri, K., von Pawel, J. Ann. Oncol. (2001) [Pubmed]
  25. Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up. Vansteenkiste, J.F., De Belie, B., Deneffe, G.J., Demedts, M.G., De Leyn, P.R., Van Raemdonck, D.E., Lerut, T.E. Lung. Cancer (2001) [Pubmed]
  26. Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Vansteenkiste, J.F., Vandebroek, J.E., Nackaerts, K.L., Weynants, P., Valcke, Y.J., Verresen, D.A., Devogelaere, R.C., Marien, S.A., Humblet, Y.P., Dams, N.L. Ann. Oncol. (2001) [Pubmed]
  27. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. Vansteenkiste, J.F., Stroobants, S.G., Dupont, P.J., De Leyn, P.R., Verbeken, E.K., Deneffe, G.J., Mortelmans, L.A., Demedts, M.G. J. Clin. Oncol. (1999) [Pubmed]
  28. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Vansteenkiste, J.F., De Leyn, P.R., Deneffe, G.J., Lerut, T.E., Demedts, M.G. Lung. Cancer (1998) [Pubmed]
  29. Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group. Vansteenkiste, J., De Leyn, P., Deneffe, G., Menten, J., Lerut, T., Demedts, M. Eur. J. Cardiothorac. Surg (1998) [Pubmed]
  30. Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group. Vansteenkiste, J.F., De Leyn, P.R., Deneffe, G.J., Lievens, Y.N., Nackaerts, K.L., Van Raemdonck, D.E., van der Schueren, E., Lerut, T.E., Demedts, M.G. Ann. Oncol. (1998) [Pubmed]
  31. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. Vansteenkiste, J.F., Stroobants, S.G., De Leyn, P.R., Dupont, P.J., Bogaert, J., Maes, A., Deneffe, G.J., Nackaerts, K.L., Verschakelen, J.A., Lerut, T.E., Mortelmans, L.A., Demedts, M.G. J. Clin. Oncol. (1998) [Pubmed]
  32. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Vansteenkiste, J.F., Stroobants, S.G., De Leyn, P.R., Dupont, P.J., Verbeken, E.K. Ann. Oncol. (1998) [Pubmed]
  33. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Vansteenkiste, J.F., De Leyn, P.R., Deneffe, G.J., Stalpaert, G., Nackaerts, K.L., Lerut, T.E., Demedts, M.G. Ann. Thorac. Surg. (1997) [Pubmed]
 
WikiGenes - Universities